1
|
Deng T, Lei F, Wang Z, Wang Y, Li G, Zhu Y, Du B, Xi X. MCP-1/CCR2 axis is involved in the regulation of γδT cells in lupus nephritis. Scand J Immunol 2023; 98:e13305. [PMID: 38441377 DOI: 10.1111/sji.13305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 05/03/2023] [Accepted: 06/06/2023] [Indexed: 03/07/2024]
Abstract
γδT cells are important innate immune cells that are involved in the occurrence and development of autoimmune diseases such as systemic lupus erythematosus (SLE). Lupus nephritis (LN) is a serious complication of SLE, characterized by the accumulation of immune cells (including γδT cells) in the target organs to participate in the disease process. Therefore, clarifying how γδT cells chemotactically migrate to target organs may be a key to developing therapeutic methods against LN. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of chemokines in LN patients and healthy controls. Real-time polymerase chain reaction (RT-PCR) and flow cytometry were used to measure the expression of chemokine receptors on the surface of γδT cells. The chemotactic migration ability of γδT cells was detected by Transwell assay. Signalling pathway activation of γδT cells was detected by Automated Capillary Electrophoresis Immunoassay and flow cytometry. The serum levels of chemokines, including monocyte chemoattractant protein-1 (MCP-1) in LN patients, were significantly increased. CCR2, the receptor of MCP-1, was also highly expressed on the surface of peripheral γδT cells in LN patients. In addition, the exogenous addition of MCP-1 can enhance chemotactic migration of γδT cells in LN patients. MCP-1 could activate STAT3 signalling in LN patients' peripheral γδT cells. γδT cells might participate in the pathogenesis of LN through MCP-1/CCR2 axis. This finding provides new opportunities for developing treatment methods against LN by targeting MCP-1/CCR2 axis.
Collapse
Affiliation(s)
- Ting Deng
- Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, China
| | - Feifei Lei
- Renmin Hospital, Hubei University of Medicine, Shiyan, China
| | - Zhongyu Wang
- Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, China
| | - Yangbin Wang
- Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, China
| | - Gang Li
- Renmin Hospital, Hubei University of Medicine, Shiyan, China
| | - Yunhe Zhu
- Renmin Hospital, Hubei University of Medicine, Shiyan, China
| | - Boyu Du
- Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, China
- Renmin Hospital, Hubei University of Medicine, Shiyan, China
| | - Xueyan Xi
- Institute of Basic Medical Science, Hubei University of Medicine, Shiyan, China
- Renmin Hospital, Hubei University of Medicine, Shiyan, China
- Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, China
| |
Collapse
|
2
|
Hara A, Shimizu M, Hamaguchi E, Kakuda H, Ikeda K, Okumura T, Kitagawa K, Koshino Y, Kobayashi M, Takasawa K, Hisada Y, Toyama T, Iwata Y, Sakai N, Wada T. Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial. Endocrinol Diabetes Metab 2020; 3:e00159. [PMID: 32704573 PMCID: PMC7375122 DOI: 10.1002/edm2.159] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 05/16/2020] [Indexed: 12/25/2022] Open
Abstract
AIMS We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C-C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. MATERIALS AND METHODS We recruited patients from nine medical institutions in Japan for this randomized, open-label, parallel two-arm pilot trial. Inclusion criteria were diagnosis of type 2 diabetes, age 30-75 years, dipstick proteinuria of ≥1+ or urinary albumin-to-creatinine ratio (UACR) of ≥30 mg/g and estimated glomerular filtration rate of ≥30 mL/min/1.73 m2. Patients were randomly assigned (1:2) using a minimization algorithm to either continuing usual care or concomitant administration of 30 mg PG per day for 12 months. The primary outcome was the change in UACR from baseline to 12 months. We also collected safety information for all patients who received at least one dose of PG. RESULTS We enrolled 29 patients, 10 were assigned to continue usual care and 19 to receive PG. Changes in UACR by PG in addition to the usual care were 25.0% (95% CI -20.4%, 96.5%, P = .33). No severe adverse events or renal events were observed during the study. CONCLUSION Although the treatment with PG was generally well tolerated, the dosage of 30 mg/d for 12 months did not reduce albuminuria when used in addition to usual care in patients with type 2 diabetes and nephropathy. Efficacy of PG should be verified in future definitive trials.
Collapse
Affiliation(s)
- Akinori Hara
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Environmental and Preventive MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| | - Miho Shimizu
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Nephrology and Laboratory MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| | - Erika Hamaguchi
- Department of Internal MedicineJapanese Red Cross Kanazawa HospitalKanazawaJapan
| | | | | | - Toshiya Okumura
- Department of Internal MedicineTonami General HospitalTonamiJapan
| | - Kiyoki Kitagawa
- Division of Internal MedicineNational Hospital Organization Kanazawa Medical CenterKanazawaJapan
| | | | - Motoo Kobayashi
- Department of Internal MedicineMunicipal Tsuruga HospitalTsurugaJapan
| | - Kazuya Takasawa
- Department of NephrologyPublic Central Hospital of Matto IshikawaHakusanJapan
| | - Yukimasa Hisada
- Department of Internal MedicineJapanese Red Cross Kanazawa HospitalKanazawaJapan
| | - Tadashi Toyama
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Nephrology and Laboratory MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| | - Yasunori Iwata
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Nephrology and Laboratory MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| | - Norihiko Sakai
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Nephrology and Laboratory MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| | - Takashi Wada
- Division of NephrologyKanazawa University HospitalKanazawaJapan
- Department of Nephrology and Laboratory MedicineFaculty of MedicineInstitute of Medical, Pharmaceutical and Health SciencesKanazawa UniversityKanazawaJapan
| |
Collapse
|
3
|
Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bartneck M, Neumann UP, Canbay A, Reeves HL, Luedde M, Tacke F, Trautwein C, Heikenwalder M, Luedde T. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol Med 2015; 6:1062-74. [PMID: 24963148 PMCID: PMC4154133 DOI: 10.15252/emmm.201403856] [Citation(s) in RCA: 317] [Impact Index Per Article: 35.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease in Western countries and often progresses to non-alcoholic steatohepatitis (NASH) leading ultimately to liver fibrosis and liver cancer. The occurrence of hepatocyte cell death—so far characterized as hepatocyte apoptosis—represents a fundamental step from benign steatosis toward progressive steatohepatitis. In contrast, the function of RIP3-dependent “necroptosis” in NASH and NASH-induced fibrosis is currently unknown. We show that RIP3 is upregulated in human NASH and in a dietary mouse model of steatohepatitis. RIP3 mediates liver injury, inflammation, induction of hepatic progenitor cells/activated cholangiocytes, and liver fibrosis through a pathway suppressed by Caspase-8. This function of RIP3 is mediated by a positive feedback loop involving activation of Jun-(N)-terminal Kinase (JNK). Furthermore, RIP3-dependent JNK activation promotes the release of pro-inflammatory mediators like MCP-1, thereby attracting macrophages to the injured liver and further augmenting RIP3-dependent signaling, cell death, and liver fibrosis. Thus, RIP3-dependent necroptosis controls NASH-induced liver fibrosis. This pathway might represent a novel and specific target for pharmacological strategies in patients with NASH. Subject Categories Digestive System; Metabolism
Collapse
Affiliation(s)
- Jérémie Gautheron
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany Interdisciplinary Centre for Clinical Research Aachen, University Hospital RWTH Aachen, Aachen, Germany
| | - Mihael Vucur
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Florian Reisinger
- Institute of Virology, Technische Universität München and Helmholtz Zentrum München für Gesundheit und Umwelt (HMGU), Munich, Germany
| | - David Vargas Cardenas
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Christoph Roderburg
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Christiane Koppe
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Karina Kreggenwinkel
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Anne Theres Schneider
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Matthias Bartneck
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Ulf Peter Neumann
- Department of Visceral and Transplantation Surgery, University Hospital RWTH Aachen, Aachen, Germany
| | - Ali Canbay
- Department of Gastroenterology and Hepatology, University Hospital University Duisburg-Essen, Essen, Germany
| | - Helen Louise Reeves
- The Liver Group, Department of Medicine, Freeman Hospital Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK
| | - Mark Luedde
- Department of Cardiology and Angiology, University Hospital Kiel, Kiel, Germany
| | - Frank Tacke
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Christian Trautwein
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| | - Mathias Heikenwalder
- Institute of Virology, Technische Universität München and Helmholtz Zentrum München für Gesundheit und Umwelt (HMGU), Munich, Germany
| | - Tom Luedde
- Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine (Department of Medicine III), University Hospital RWTH Aachen, Aachen, Germany
| |
Collapse
|
4
|
Hickman DA, Syal G, Fausther M, Lavoie EG, Goree JR, Storrie B, Dranoff JA. MCP-1 downregulates MMP-9 export via vesicular redistribution to lysosomes in rat portal fibroblasts. Physiol Rep 2014; 2:2/11/e12153. [PMID: 25413315 PMCID: PMC4255798 DOI: 10.14814/phy2.12153] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Portal fibroblasts (PF) are one of the two primary cell types contributing to the myofibroblast population of the liver and are thus essential to the pathogenesis of liver fibrosis. Monocyte chemoattractant protein‐1 (MCP‐1) is a known profibrogenic chemokine that may be of particular importance in biliary fibrosis. We examined the effect of MCP‐1 on release of matrix metalloproteinase‐9 (MMP‐9) by rat PF. We found that MCP‐1 blocks PF release of MMP‐9 in a posttranslational fashion. We employed an optical and electron microscopic approach to determine the mechanism of this downregulation. Our data demonstrated that, in the presence of MCP‐1, MMP‐9‐containing vesicles were shunted to a lysosome‐like compartment. This is the first report of a secretory protein to be so regulated in fibrogenic cells. Portal fibroblasts are resident liver cells that contribute to liver fibrosis. MCP‐1 induces profibrogenic changes in portal fibroblasts. Here, we found that MCP‐1 also downregulates function of the matrix metalloproteinase MMP9 via shunting of vesicles to a lysosomal compartment.
Collapse
Affiliation(s)
- DaShawn A Hickman
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Gaurav Syal
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Michel Fausther
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Elise G Lavoie
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Jessica R Goree
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Brian Storrie
- Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Jonathan A Dranoff
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| |
Collapse
|
5
|
Yamada S, Wang KY, Tanimoto A, Guo X, Nabeshima A, Watanabe T, Sasaguri Y. Histamine receptors expressed in circulating progenitor cells have reciprocal actions in ligation-induced arteriosclerosis. Pathol Int 2014; 63:435-47. [PMID: 24200155 DOI: 10.1111/pin.12091] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 08/09/2013] [Indexed: 12/01/2022]
Abstract
Histamine is synthesized as a low-molecular-weight amine from L-histidine by histidine decarboxylase (HDC). Recently, we demonstrated that carotid artery-ligated HDC gene-deficient mice (HDC(-/-)) showed less neointimal formation than wild-type (WT) mice, indicating that histamine participates in the process of arteriosclerosis. However, little is known about the roles of histamine-specific receptors (HHRs) in arteriosclerosis. To define the roles of HHRs in arteriosclerosis, we investigated intimal remodeling in ligated carotid arteries of HHR-deficient mice (H1R(-/-) or H2R(-/-)). Quantitative analysis showed that H1R(-/-) mice had significantly less arteriosclerogenesis, whereas H2R(-/-) mice had more, as compared with WT mice. Bone marrow transplantation from H1R(-/-) or H2R(-/-) to WT mice confirmed the above observation. Furthermore, the increased expression of monocyte chemoattractant protein (MCP-1), platelet-derived growth factor (PDGF), adhesion molecules and liver X receptor (LXR)-related inflammatory signaling factors, including Toll-like receptor (TLR3), interleukin-1 receptor (IL-1R) and tumor necrosis factor receptor (TNF-R), was consistent with the arteriosclerotic phenotype of H2R(-/-) mice. Peripheral progenitor cells in H2R(-/-) mice accelerate ligation-induced arteriosclerosis through their regulation of MCP-1, PDGF, adhesion molecules and LXR-related inflammatory signaling factors. In contrast, peripheral progenitor cells act to suppress arteriosclerosis in H1R(-/-) mice, indicating that HHRs reciprocally regulate inflammation in the ligation-induced arteriosclerosis.
Collapse
Affiliation(s)
- Sohsuke Yamada
- Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu
| | | | | | | | | | | | | |
Collapse
|